AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 12 min read$PGEN

Thomasian Harry Jr. sold $183K of PGEN

Thomasian Harry Jr. (Chief Financial Officer) sold 41,884 shares of PRECIGEN, INC. (PGEN) at $4.36 ($0.18M total) on 2026-05-28.

Original reporting
SEC EDGAR · Thomasian Harry Jr.
Published Jun 1, 2026, 8:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PGEN
Neutral
medium confidence
Mentioned
$PGEN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

This provides a datapoint on insider behavior (open-market sale) but does not introduce new company fundamentals like trial results, guidance, financing, or contracts.

02

Market read

Traders may monitor for follow-through selling pressure, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

Insider sales often occur for tax/financial planning; without context on total compensation, prior sales, or remaining holdings, signal strength is weak.

Relevance 6/10Novelty 6/10Timing: after SEC filing (filed 2026-06-01) for a sale executed 2026-05-28

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure by Precigen’s CFO.

Company-level read

Ticker impact

$PGENNeutralMedium confidence
Context

SEC Form 4 shows CFO Harry Jr. sold 41,884 shares of Precigen at $4.36/share, disclosing direct insider selling activity.

Expected impact

Low near-term impact; any move is likely sentiment-driven and limited unless accompanied by other news.

Evidence & confidence

The filing is an ownership-change disclosure with no new operating/financial information; also explicitly notes no 10b5-1 plan, which can raise attention but still lacks a direct causal catalyst.

Market effects

Sector

Limited read-across to biotech/clinical-stage sentiment; insider selling is company-specific and typically not sector-wide.

Regional

None indicated; US-listed microcap/small-cap style flow effects only.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be routine liquidity/portfolio rebalancing; absence of a 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • issuer
    PRECIGEN, INC.

    Company whose CFO reported an open-market sale of shares via SEC Form 4.

  • insider
    Thomasian Harry Jr.

    Precigen CFO who sold 41,884 shares at $4.36/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PGEN insider trading history →

Related articles

AUG 21
$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.com3 min
AUG 12
$PGENMed

Precigen (PGEN) Q2 2026 Earnings Call Transcript

Precigen (PGEN) reported Q2 2026 PAPZIMEOS net revenue of $53.1 million, up 145.8% sequentially from $21.6 million, and first quarterly net income of $20.1 million, or $0.05 per diluted share. Gross margin was 95% but management expects normalization to high 80% to low 90%. Cash and investments were $38.7 million at June 30, 2026.

fool.com6 min
AUG 4
$PGENMed

PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and bro

SEC EDGAR 8-K6 min
JUN 1
$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.

newswise.com4 min